OverviewSuggest Edit

WuXi Biologics (药明生物) is a company operating as an open-access technology platform for biologics drug development. It helps organizations discover, develop, and manufacture biologics from concept to commercial manufacturing. The company also delivers cell line development and analytical protein characterization services.

TypePublic
Founded2010
HQWuxi, CN
Websitewuxibiologics.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Dec 2020)6,646(+17%)
Job Openings132
Revenue (FY, 2020)¥5.6 B(+41%)
Share Price (Sept 2021)$121.5
Cybersecurity ratingAMore

Key People/Management at WuXi Biologics

Weichang Zhou

Weichang Zhou

Chief Technology Officer, Executive Vice President
Christine Lu-Wong

Christine Lu-Wong

Chief Financial Officer, Executive Vice President
Jijie Gu

Jijie Gu

Chief Scientific Officer, Executive Vice President
Ge Li

Ge Li

Chairman
Jian Dong

Jian Dong

CEO, WuXi Vaccines, Head of Global Engineering,
Jing Li

Jing Li

Senior Vice President, Discovery Service
Show more

WuXi Biologics Office Locations

WuXi Biologics has offices in Wuxi, Hangzhou, Shanghai, Suzhou and in 3 other locations
Wuxi, CN (HQ)
108, Meiliang Road, Mashan
Hangzhou, CN
Zhejiang
Shanghai, CN
Waigaoqiao Free Trade Zone
Suzhou, CN
Jiangsu
Wuxi, CN
Hi-Tech District
George Town, KY
Ugland House, Grand Cayman
Show all (9)

WuXi Biologics Financials and Metrics

WuXi Biologics Revenue

Embed Graph
View revenue for all periods
WuXi Biologics's revenue was reported to be ¥5.61 b in FY, 2020 which is a 40.9% increase from the previous period.
CNY

Revenue (FY, 2020)

5.6b

Revenue growth (FY, 2019 - FY, 2020), %

40.9%

Gross profit (FY, 2020)

2.5b

Gross profit margin (FY, 2020), %

45.1%

Net income (FY, 2020)

1.7b

Market capitalization (21-Sept-2021)

511.5b

Closing stock price (21-Sept-2021)

121.5

Cash (31-Dec-2020)

7.1b

EV

507.8b
WuXi Biologics's current market capitalization is $511.5 b.
Annual
CNYFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.6b2.5b4.0b5.6b

Revenue growth, %

57%57%41%

Cost of goods sold

958.3m1.5b2.3b3.1b

Gross profit

660.6m1.0b1.7b2.5b
Half Year
CNYH1, 2018H1, 2019H1, 2020

Revenue

1.1b1.6b1.9b

Cost of goods sold

639.7m936.1m1.2b

Gross profit

414.7m671.0m787.3m

Gross profit Margin, %

39%42%40%
Annual
CNYFY, 2017FY, 2018FY, 2019FY, 2020

Cash

503.9m4.1b6.2b7.1b

Accounts Receivable

314.3m762.9m1.3b2.3b

Prepaid Expenses

927.0k3.2m4.1m6.6m

Inventories

135.5m227.2m399.4m1.1b
Half Year
CNYH1, 2018H1, 2019H1, 2020

Cash

4.4b2.9b3.7b

Accounts Receivable

576.7m872.0m1.7b

Prepaid Expenses

8.2m7.2m7.1m

Inventories

243.3m318.9m611.8m
Annual
CNYFY, 2017FY, 2018FY, 2019

Depreciation and Amortization

122.7m145.9m224.4m

Inventories

(138.9m)(95.7m)(94.0m)

Accounts Payable

203.9m183.5m579.6m

Cash From Operating Activities

360.3m761.6m1.2b
Half Year
CNYH1, 2018H1, 2019H1, 2020

Cash From Operating Activities

122.2m221.9m430.6m

Purchases of PP&E

(525.0m)(753.7m)(2.9b)

Cash From Investing Activities

533.6m(1.4b)(4.0b)

Long-term Borrowings

(8.9m)(165.2m)
CNYFY, 2017

Revenue/Employee

636.6k

Financial Leverage

1.2 x
Show all financial metrics

WuXi Biologics Operating Metrics

WuXi Biologics's Backlog was reported to be $11.3b in FY, 2020.
FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019H1, 2020Oct, 2020FY, 2020

Pre-clinical Projects

909897106121141161169

Backlog

$1.48 b$1.78 b$3.6 b$5.1 b$10.3 b$11.32 b

Integrated Projects

161187205224250286312334

New Projects

575972
Show all operating metrics

WuXi Biologics Acquisitions / Subsidiaries

Company NameDateDeal Size
Drug Product Plant from BayerApril 21, 2020
WuXi Biologics Alliance Limited
WuXi Biologics (Chengdu) Co., Ltd
WuXi Biologics Co., Ltd
WuXi Biologics Conjugation Co., Ltd.
WuXi Biologics Germany GmbH
WuXi Biologics (Hangzhou) Co., Ltd.
WuXi Biologics HealthCare Venture
WuXi Biologics HealthCare Venture (Cayman) Inc
WuXi Biologics HealthCare Venture Hong Kong Holding Limited
Show more

WuXi Biologics Revenue Breakdown

Embed Graph

WuXi Biologics revenue breakdown by geographic segment: 43.9% from PRC, 44.2% from North America, 8.0% from Europe and 4.0% from Other

Human Capital Metrics

WuXi Biologics's employees are reported to be approximately 55% female and 45% male.
Embed Graph
Show all human capital metrics

WuXi Biologics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

WuXi Biologics Online and Social Media Presence

Embed Graph

WuXi Biologics News and Updates

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs

VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320, the company's COVID-19 vaccine...

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS - CoV - 2 s - proteins for BVX - 0320 and CoviDTH Programs

BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS - CoV - 2 s - proteins for BVX - 0320 and CoviDTH Programs

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturing License from Japan's Minister of Health, Labor and Welfare (MHLW) for its drug substance facility (MFG2) at Wuxi city, China after a 2…

WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date

Successfully completed 12 regulatory inspections so far this year WUXI, China, Sept. 1, 2021 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has received the Manufacturing License from...

WuXi Biologics earns local nod for expansion to growing MA manufacturing site

WuXi Biologics’ Massachusetts manufacturing site isn’t even up and running yet, and it’s already getting an upgrade.

WuXi Biologics earns local nod for expansion to growing MA manufacturing site

WuXi Biologics earns local nod for expansion to growing MA manufacturing site
Show more

WuXi Biologics Blogs

The Reactory Summit

World ADC Conference

Wuppertal, Germany Site

Hangzhou, China Site

Ming Tu Joins WuXi Biologics as Co-Chief Financial Officer

Shanghai, China, August 23, 2021 – WuXi Biologics (“WuXi Bio”) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that industry veteran Ming Tu has joined the company as Executive Vice President and Co-Chief Financial Officer (Co-CFO), reporting to C…
Show more

WuXi Biologics Frequently Asked Questions

  • When was WuXi Biologics founded?

    WuXi Biologics was founded in 2010.

  • Who are WuXi Biologics key executives?

    WuXi Biologics's key executives are Weichang Zhou, Christine Lu-Wong and Jijie Gu.

  • How many employees does WuXi Biologics have?

    WuXi Biologics has 6,646 employees.

  • What is WuXi Biologics revenue?

    Latest WuXi Biologics annual revenue is ¥5.6 b.

  • What is WuXi Biologics revenue per employee?

    Latest WuXi Biologics revenue per employee is ¥844.5 k.

  • Who are WuXi Biologics competitors?

    Competitors of WuXi Biologics include Evotec, Catalent and Lonza.

  • Where is WuXi Biologics headquarters?

    WuXi Biologics headquarters is located at 108, Meiliang Road, Mashan, Wuxi.

  • Where are WuXi Biologics offices?

    WuXi Biologics has offices in Wuxi, Hangzhou, Shanghai, Suzhou and in 3 other locations.

  • How many offices does WuXi Biologics have?

    WuXi Biologics has 9 offices.